Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data

Song, Zhuo; Zou, Kun; Zou, Lijuan

doi:10.3389/fonc.2022.1045481

Cited by 8 publications

(2 citation statements)

References 122 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Essa glicoproteína de membrana está superexpressa em células de câncer cervical e está associada ao mau prognóstico da doença 35 . Embora o tisotumabe seja uma terapia de primeira linha, outros fármacos mAb podem ser utilizados, como o pembrolizumabe 36 .…”

Section: Discussionunclassified

Fármacos Anticorpos Monoclonais para o Tratamento do Câncer: uma Perspectiva Brasileira

Menezes,

Theisen,

Flores

et al. 2024

Rev. Bras. Cancerol.

View full text Add to dashboard Cite

Introdução: Os anticorpos monoclonais (mAb) são alternativa terapêutica importante no tratamento do câncer. Porém, o acesso a essa terapia é desigual entre países com diferentes rendas. Objetivo: Comparar os fármacos mAb aprovados para uso contra câncer nos EUA com os aprovados no Brasil e discutir, por meio do mecanismo de ação, alternativas terapêuticas disponíveis. Método: A lista de fármacos mAb aprovados pelo FDA foi coletada de publicação prévia e complementada com dados presentes no site dessa agência, assim como mecanismo de ação, data de aprovação e indicações clínicas foram obtidos das bulas dos medicamentos nesse mesmo site. Da mesma forma, os dados de data de aprovação pela Anvisa foram obtidos em consultas ao site dessa agência. Os fármacos foram tabelados e organizados conforme características estruturais e separados em quatro grandes grupos, conforme seu mecanismo de ação. Resultados: Até 2022, 48 mAb foram aprovados para uso contra o câncer pelo FDA. Destes, 37 foram aprovados pela Anvisa para uso no Brasil, com tempo médio entre aprovação no exterior e no Brasil próximo a dois anos. A maioria dos mAb são humanos ou humanizados (77%) e variam bastante com relação ao mecanismo de ação, sendo o antígeno de linfócitos B CD20 e o checkpoint imunológico PD-1/PD-L1 os principais alvos dos mAb avaliados. Conclusão: Apesar de alguns fármacos aprovados no exterior ainda não estarem aprovados no Brasil, o atraso para registro não parece estar relacionado à demora da Anvisa. Além disso, para a maioria dos casos de fármacos ainda não aprovados no Brasil, existem alternativas terapêuticas disponíveis.

show abstract

Section: Discussionunclassified

Fármacos Anticorpos Monoclonais para o Tratamento do Câncer: uma Perspectiva Brasileira

Menezes,

Theisen,

Flores

et al. 2024

Rev. Bras. Cancerol.

View full text Add to dashboard Cite

show abstract

“…Finally, studies have shown an increase in the total mutational burden (TMB) rate in CC (approximately 5-6 mutations per megabase) ( 23 , 24 ). Thus, immune checkpoints inhibitors (ICIs) including inhibitors of PD-1 and PD-L1, as well as inhibitors of CTLA-4 have been evaluated in several CC trials ( 5 , 25 ).…”

Section: Systemic Treatment For Recurrent or Metastatic Cervical Cancermentioning

confidence: 99%

The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review

et al. 2023

View full text Add to dashboard Cite

Despite human papillomavirus vaccination and screening, in about 5% of cases, cervical cancer (CC) is discovered at an initial metastatic stage. Moreover, nearly one-third of patients with locally advanced CC (LACC) will have a recurrence of their disease during follow-up. At the stage of recurrent or metastatic CC, there are very few treatment options. They are considered incurable with a very poor prognosis. For many years, the standard of care was the combination of platinum-based drug and paclitaxel with the possible addition of bevacizumab. The most recent years have seen the development of the use of immune checkpoint inhibitors (ICIs) (pembrolizumab, cemiplimab and others) in patients with CC. They have shown long term responses with improved overall survival of patients in 1st line (in addition to chemotherapy) or 2nd line (as monotherapy) treatment. Another emerging drug is tisotumab vedotin, an antibody-drug conjugate targeting tissue factor. Radiation therapy (RT) often has a limited palliative indication in metastatic cancers. However, it has been observed that RT can induce tumor shrinkage both in distant metastatic tumors beyond the radiation field and in primary irradiated tumors. This is a rarely observed phenomenon, called abscopal effect, which is thought to be related to the immune system and allows a tumor response throughout the body. It would be the activation of the immune system induced by the irradiation of cancer cells that would lead to a specific type of apoptosis, the immunogenic cell death. Today, there is a growing consensus that combining RT with ICIs may boost abscopal response or cure rates for various cancers. Here we will review the potential abscopal effect of immune-radiation therapy in metastatic cervical cancer.

show abstract

Immunocompetent PDMS‐Free Organ‐on‐Chip Model of Cervical Cancer Integrating Patient‐Specific Cervical Fibroblasts and Neutrophils

Kromidas,

Geier,

Weghofer

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Despite preventive measures and available treatments, cervical cancer still ranks as the fourth most prevalent cancer among women worldwide and remains the leading cause of cancer death in women in many developing countries. To gain further insights into pathogenesis and to develop novel (immuno)therapies, more sophisticated human models recreating patient heterogeneities and including aspects of the tumor microenvironment are urgently required. We introduce a novel PDMS‐free microfluidic platform, designed specifically for the generation and cultivation of cervical cancerous tissue. The microscale open‐top tissue chambers of the cervical cancer‐on‐chip (CCoC) enable facile generation and long‐term cultivation of SiHa spheroids in co‐culture with donor‐derived cervical fibroblasts. The resulting 3D tissue emulates physiological architecture and allows dissection of distinct effects of the stromal tissue on cancer viability and growth. Treatment with cisplatin at clinically‐relevant routes of administration and dosing highlights the platform's applicability for drug testing. Moreover, the model is amenable for integration and recruitment of donor‐derived neutrophils from the microvasculature‐like channel into the tissue, all while retaining their ability to produce neutrophil extracellular traps (NETs). In the future, the immunocompetent CCoC featuring donor‐specific primary cells and tumor spheroids has the potential to contribute to the development of new (immuno)therapeutic options.This article is protected by copyright. All rights reserved

show abstract

Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data

Cited by 8 publications

References 122 publications

Fármacos Anticorpos Monoclonais para o Tratamento do Câncer: uma Perspectiva Brasileira

Fármacos Anticorpos Monoclonais para o Tratamento do Câncer: uma Perspectiva Brasileira

The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review

Immunocompetent PDMS‐Free Organ‐on‐Chip Model of Cervical Cancer Integrating Patient‐Specific Cervical Fibroblasts and Neutrophils

Contact Info

Product

Resources

About